- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1]
- uMRD response rates were consistent independent of risk factors, including 17p deletion, IgVH mutation and TP53 mutations[1]
PR Newswire
NORTH CHICAGO, Ill., June 15, 2018
